As Founder, President and CEO of Virtify, Dr. Satish Tadikonda has developed Virtify into a market leader in structured content management for life sciences. With more than 21 years of experience in the life sciences industry, Dr. Tadikonda's expertise spans drug and medical device development, and software systems development. Over the course of his career, he has helped develop a number of long-term strategic initiatives and quick win solutions for clients. In addition to a deep understanding of discovery and development processes, Dr. Tadikonda has hands-on experience with a number of R&D and commercial systems, including systems for optimizing electronic submissions, clinical trial and data management, clinical trial disclosure, global labeling, medical imaging, product life cycle management, and manufacturing operations. Dr. Tadikonda also plays a leadership role in the development of global regulatory standards and is an active participant in a variety of electronic standards committees.
Dr. Tadikonda has been instrumental in the development of the Virtify software suite and has helped develop Virtify's comprehensive professional services portfolio to enhance quality and compliance for some of the world's leading life sciences companies.
Prior to Virtify, Dr. Tadikonda was the founder of Tribiosys, Inc., a Cambridge, MA-based scientific consulting company. Before this venture, he was the Founder, CEO and President of Enmed, Inc., a clinical trial and data management systems development company. At Enmed, Dr. Tadikonda was responsible for conceptualizing and developing a suite of products designed to improve the speed and efficiency of clinical development, including electronic data capture and real-time reporting of serious adverse events. The suite of products supported eCRF generation, investigator, site, clinical data, medical image and document management.
Prior to Enmed, Dr. Tadikonda served as Director of Imaging Science at EPIX Medical, Inc., where he led the company's imaging department and helped develop innovative techniques to visualize vascular structures. Early in his career, he was a lead engineer with Hewlett-Packard Medical Products Group, working on developing innovative MRI, Ultrasound and Telemedicine products.
Dr. Tadikonda holds a Doctorate in Electrical and Computer Engineering from the University of Iowa, and a Bachelor of Technology in Electrical and Electronics Engineering from Birla Institute of Technology and Science, India. Dr. Tadikonda has published and presented more than 30 articles in peer-reviewed journals and international conferences on topics in global labeling, medical imaging, clinical trial data management/disclosure, and technology in the life sciences.
Mike Webb has more than 25 years of experience in healthcare and life sciences. Most recently, he was the CEO of Ascent Therapeutics, a venture-backed company focusing on developing pepducins, a new biology platform for drug discovery. Prior to founding Ascent, he was the CEO of EPIX Pharmaceuticals, Inc. from 1994 through 2005. During this period, EPIX grew from a venture-backed startup to the world leader in discovery and development of pharmaceuticals for imaging with MRI, achieving worldwide approval for its lead product and completing numerous public financings and corporate partnerships, including an IPO. Mr. Webb joined EPIX from CIBA, where he was most recently Senior Vice President, Worldwide Marketing and Strategic Planning of CIBA Diagnostics, responsible for global marketing, program management, corporate planning, business development, and licensing. Prior to CIBA, Mr. Webb was a senior consultant at Booz, Allen & Hamilton, specializing in healthcare and life sciences.
Mr. Webb holds Bachelors degrees in Biochemistry and Economics from the University of Kansas, Summa Cum Laude, and an MA in International Relations from Sussex University in the UK, completing his thesis on "Pharmaceuticals Policy and the World Health Organization." In addition, Mr. Webb holds an MBA degree with honors from the Kellogg Graduate School of Management at Northwestern University. He currently serves on the boards of the Massachusetts Biotechnology Council, where he is past Chairman, the Kellogg Center for Biotechnology at Northwestern and is a Senior Advisor to Johnston and Blakely, a life sciences investment banking firm.
Bob founded Tudor Growth Equity in 1995. Prior to Tudor, Bob was a Vice President at the Boston based LBO firm, Carlisle Capital. He also served as CEO of a start-up software company and as a management consultant at Bain & Company.
Bob brings over 15 years of investing and operating experience to the group, and has focused mostly on IT infrastructure, enterprise software and business services. Bob serves on the Board of Directors of Allegro Development Corporation, Aspect Ratio, Intelligrated, Inc., Thorne Research, Inc., and Virtify, Inc. He previously served as a director of Art Technology Group (NASDAQ: ARTG), Interactive Video Technologies, Enherent (OTC:ENHT), and Classic Sports Network (Disney).
Bob graduated from Washington and Lee University, with a BS in Accounting and Business Administration, and received his MBA from Harvard Business School.
Mr. Stansky was a Managing Director of Tudor Growth Equity, which he joined in January 1994 and retired from active investment management on December 31, 2008. From 1985 to 1994, Mr. Stansky was a portfolio manager at Wellington Management. Mr. Stansky holds a B.A. in accounting from the University of Massachusetts and an M.B.A. from Harvard Business School. Mr. Stansky is a Certified Public Accountant and a Chartered Financial Analyst.